Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose
1. VERV has positive Phase 1b trial data for VERVE-102 in HeFH and CAD patients. 2. ERTE-102's single infusion reduced LDL-C by up to 69%. 3. FDA Fast Track designation granted for VERVE-102 targeting hyperlipidemia. 4. Final data from Heart-2 trial expected in H2 2025. 5. VERV plans to initiate Phase 2 trial in H2 2025, pending clearance.